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ABSTRACT  
Objective: The present study was performed to determine in vitro antidiabetic effect of neohesperidin. To evaluate inhibitory effect of 
neohesperidin on α-amylase and α-glucosidase diabetes causing enzyme. 
Methods and Materials: Invitro carbohydrate metabolizing enzyme based inhibitory methods were used to determine antidiabetic effect of 
neohesperidin. Alpha (α)-amylase inhibitory assay was performed using different sources i.e. wheat alpha (α)-amylase enzyme, salivary alpha 
(α)-amylase and fungal alpha (α)-amylase assay. Alpha (α)-glucosidase inhibitory assay was performed using alpha (α)-glucosidase (B. 
stearothermophil), alpha (α)-glucosidase rat intestine and alpha (α)-glucosidase from baker’s yeast. Sucrase inhibitory assay from rat small 
intestine. 
Result: Neohesperidin possess a potent anti-diabetic by significantly inhibiting alpha amylase activity. 
Conclusion: It was concluded that enzyme inhibitory activity of neohesperidin shown a significantly higher inhibitory activity on alpha-
amylase in comparision to alpha-glucosidase & Sucrase enzymes.  
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INTRODUCTION: 
Neohesperidin (hesperetin-7-neohesperidoside) are 
flavanones glycosides unique to Citrus and specific citrus 
cultivars belongs to family rutaceae.[1,2]They are weak-polar 
molecules with bitter taste and their content or ratio can be 
used as citrus taxonomic markers [3,4] or indicators for 
identification of authentic orange juice (Citrus sinensis).[5] 
They share the same neohesperidose (2-O-a-
Lrhamnopyranosyl-b-D-glucopyranose), which determines 
their bitterness, as naturally occurred flavonoids; they are 
known dietary antioxidants that have diverse biological 
activities. [6]It have been reported that neohesperidin 
possess antioxidant[7, 8, 9],antidiabetic [10-13], hypolipidemic 
effects [14-17], protection against cardiovascular diseases [18], 
anti-inflammatory[19-21], anti-arthritic activity, anti-
carcinogenic [22] and antimicrobial property [23, 24].Natural 
amylase and α-glucosidase inhibitors from food-grade plant 
sources offer an attractive strategy to control post-prandial 
hyperglycaemia. Natural inhibitors from plants, which have 
been shown to have a low inhibitory effect against α-
amylase activity and a strong inhibition activity against α-
glucosidase, can be used as an effective therapy for 
postprandial hyper glycaemia with minimal side effects. [25]  
MATERIALS AND METHODS 
Chemicals and reagents: 
Alpha-glucosidase enzyme, Neohesperidin, 4-Nitrophenyl α-
D-glucopyranoside, Calcium acetate (Sigma - Aldrich, USA); 
Potassium dihydrogen orthophosphate, Sodium hydroxide 
pellets, Sucrose, Maleic acid (Loba Chemie PVT LTD Mumbai 
India); Sodium potassium tartarate, Starch soluble, Yeast 
powder(Fizmerk India Chemicals); petroleum ether (Samar 
chemicals, India); Acarbose (Bayer pharmaceuticals Pvt. Ltd, 
Baddi); Sodium dihydrogen orthophosphate (Molychem, 
Mumbai) and Sodium carbonate anhydrous (Merk Life 
Science Private Limited, Mumbai) etc.  
Chemistry of neohesperidine: 
Its IUPAC name is methoxyflavanone-7-beta-neohesperido-
side 3,5,7,4 tetrahydroxy, it is also known as hesperetin 7-O-
neohesperidoside. Structurally it belongs to the class of 
flavanones. Its molecular formula isC28H34O15 and molecular 
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weight is 610.5606g/mol. It is stored in cold condition i.e. 2-
8 ℃.  
 
Enzyme inhibitory activities 
Wheat alpha amylase inhibitory activity: 
500 gm of malted whole wheat flour was added slowly with 
stirring to 1 liter of 0.2% calcium acetate solution at room 
temperature and continuously stirred for 2 hours on a 
stirrer. The suspension was then centrifuged at 40ºC at 
12000 rpm for 10 minutes. The resultant clear brown 
supernatant was stored at 2°C to 3°C prior to heat treatment. 
Then inactivates β-amylase by heat treatment, since beta 
amylase interferes with the enzymatic determination of 
alpha amylase it was inactivated by heating the extract at 
70°C for 15 minutes. Alpha amylase is resistant to 
inactivation by this treatment at pH between 6.5 and 8.0. 
The pH of the extract was first adjusted to pH 6.6 with cold 
4% ammonium hydroxide. Heat treatment was carried out at 
85°C to 90°C and other at 72°C to 74°C using a water bath 
with continuous stirring. The extract was then cooled to 2°C 
to 3°C until use.  
The assay mixture containing 200 μl of 0.02M sodium 
phosphate buffer, 20 μl of enzyme and the different 
concentration of (20-100) μg/ml were incubated for 10 
minutes at room temperature followed by addition of 200 μl 
of starch in all test tubes. The reaction was terminated with 
the addition of 400 μl DNS reagent and placed in boiling 
water bath for 5 minutes, cooled and diluted with 15 ml of 
distilled water and absorbance was measured at 540 nm. 
The control samples were prepared without any drug 
sample. It can be calculated according to the following 
formula:  
Percentage inhibition= Absorption control – Absorption 
sample × 100/Absorption control 
Salivary enzymes assay: 
Saliva samples were collected from the rabbit mouth with 
help of cotton and dissolve in 0.1 M Tris buffer (pH 7.0), 
proper carefully handling the animal and saliva obtained to 
help of rabbit mouth guard and saliva secretion flow rate  
increased to used sialogogue drug dose given to rabbit. It 
was centrifuged at 13,000 rpm for 20 min. An aliquot of the 
supernatant was diluted with water.  The collected 
supernatant containing salivary enzyme was assayed by the 
method reported previously with a slight modification. The 
assay mixture containing 200 μl of 0.02M sodium phosphate 
buffer, 20 μl of enzyme and the deferent concentration of 
(20-100) μg/ml were incubated for 10 minutes at room 
temperature followed by addition of 200 μl of starch in all 
test tubes. The reaction was terminated with the addition of 
400 μl DNS reagent and placed in boiling water bath for 5 
minutes, cooled and diluted with 15 ml of distilled water and 
absorbance was measured at 540 nm. The control samples 
were prepared without any drug sample. It can be calculated 
according to the following formula:  
Percentage inhibition= Absorption control – Absorption 
sample × 100/Absorption control 
Fungal α-amylase inhibitory activity: 
The assay mixture containing 200 μl of 0.02M sodium 
phosphate buffer, 20 μl of enzyme and the plant extracts in 
concentration range 20-100 μg/ml were incubated for 10 
minutes at room temperature followed by addition of 200 μl 
of starch in all test tubes. The reaction was terminated with 
the addition of 400 μl DNS reagent and placed in boiling 
water bath for 5 minutes, cooled and diluted with 15 ml of 
distilled water and absorbance was measured at 540 nm.[26] 
The control samples were prepared without any drug 
sample. It can be calculated according to the following 
formula:  
Percentage inhibition= Absorption control – Absorption 
sample × 100/Absorption control 
Sucrase enzyme inhibition activity: 
Isolated rat intestine was chilled with ice cold 80 mM 
phosphate buffer. The intestine was then cut open, the 
mucosa scraped off with a piece of glass rod and 
homogenized with four parts (v/v) of cold buffer. Nuclei and 
large cell debris were removed by centrifugation at 2000 to 
4000 rpm for 10 mins and supernatant aliquoted into 1.5 ml 
vials and stored at -20 ºC. Enzyme inhibitory assay was 
performed according to the method of Honda and Hara. The 
enzyme solution 10µl and varying concentrations of the test 
sample  (20-100µg) were incubated together for 10 minutes 
at 37 °C, and the volume was made up to 200 µL with 
maleate buffer (pH 6.0). The enzyme reaction was started by 
adding 100 µl sucrose solution (60 mM). After 30 minutes, 
the reaction was terminated by adding 200 µL of 3, 5- 
dinitrosalicylic acid reagent and treating the mixture in a 
boiling water bath for 5 minutes. The absorbance of the 
solution was read at 540 nm.It can be calculated according 
to the following formula:  
Percentage inhibition= Absorption control – Absorption 
sample × 100/Absorption control 
Where, Absorbance control is the absorbance of the control 
reaction (containing all reagents except the test sample), and 
the Absorbance sample is the absorbance of the test sample. 
An untreated enzyme solution was used as the control. All 
the experiments were carried out in triplicate.  
Alpha- glucosidase enzyme inhibition activity: 
α-glucosidase type IV enzyme obtained from B. 
stearothermophiluswas dissolved in 0.5 M phosphate buffer 
(pH 6.5) at the rate of 3 U/ml.The α-glucosidase inhibitory 
activity was determined by measuring the release of 4-
nitrophenol from p-nitrophenyl α-D glucopyranoside. The 
assay mixtures for these experiments contained 0.3 ml of 
10mM p-nitrophenyl α-D-glucopyranoside, 1.0 ml of 
potassium phosphate (0.1M, pH: 6.8), 0.2 ml of enzyme 
solution and 0.2 ml of inhibitor test sample , all in a final 
volume of 1.7 ml. Following an incubation time of 30 min at 
37º C, the reaction was terminated by the addition of 2.0 ml 
of 100 mM sodium carbonate. [152] The liberated p-
nitrophenol was determined at 400 nm using 
spectrophotometer.The % inhibition rates were calculated 
using the formula, 
Inhibition (%) = 100(Absorbance Control - Absorbance 
Test/Absorbance Control) 
Suitable reagent blank and inhibitor controls were also 
carried out and subtracted. Dose dependent variation in the 
α-glucosidase inhibition was measured using 25 μl to 200 μl 
of the aqueous extracts. (A110)(A105) 
Method of α-glucosidase rat small intestine: 
Rat small intestine homogenate was prepared according to 
the method described by Loss wet al., (1964) with slight 
modifications. The small intestine of male Wistar rats 
weighing 180g was collected after sacrificing the animal 
under anesthesia. The Small intestine was removed and 
washed with saline (30ml of 0.9% NaCl) and epithelial layer 
(mucosal tissue) was collected by scraping the luminal 
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surface firmly with a spatula and placed in ice cold 0.9% 
NaCl. The intestine was minced with a surgical knife and 
homogenized using in 50 ml of 0.1 M potassium phosphate 
buffer of pH 6.8. After 30 min, the homogenates were 
centrifuged for 30 min at 10,000 rpm at 4°C. The 
supernatant fraction contained rat small intestinal α-
glucosidase. The Supernatant was used as crude enzyme 
source. (A104)Alpha-glucosidase inhibitory activity was 
assayed according to the method of Honda and Hara. 
Enzyme solution (10 μL) and three fractions of test sample 
(10–50 μL) were incubated together for 10 min at 37°C and 
the volume was made up to 210 μL with maleate buffer, pH 
6.0. The enzyme reaction was started by adding 200 μL of 2 
mMp-nitrophenyl-α-d-glucopyranoside solution and further 
incubated at 37°C for 30 min. The reaction was terminated 
by treating the mixture in a boiling water bath for 5 min. 
After the addition of 1.0 mL of 0.1 M disodium hydrogen 
phosphate solution, absorption of the liberated p-
nitrophenol was read at 400 nm. Enzyme inhibition assay 
was measured based on solving the substrate to produce 
colored products. (7)It can be calculated according to the 
following formula:  
Percentage inhibition= Absorption control – Absorption 
sample × 100/Absorption control 
Assay of Alpha-glucosidase from baker’s yeast: 
The yeast glucosidase was dissolve in 100 mM phosphate 
buffer, pH 6.8 was used as enzyme source. 100mMP-
nitrophenyl-α-d-glucopyranoside was used as substrate. The 
test sample was weighted and dissolves with water to get a 
concentration of 20-100 μg/ml. the test sample was mixed 
with 320 μl of 100mM phosphate buffer (pH 6.8) and 50 μl of 
10mM PNPG in the buffer and then it was incubated at 30º C  
for 5 minutes. After the incubation, 20 μl of the buffer 
containing 0.5 mg/ml of the enzyme was added and further 
incubated at 30º C for 5 minutes. Finally, 3.0 ml of 50 mM 
sodium hydroxide was measured at 410 nm on a 
spectrophotometer.The enzyme without test sample was 
used as a control.The IC50 values were determine from plots 
of percent inhibition Vs log inhibitor concentration and 
calculated by non-linear regression analysis from the mean 
inhibitory values.[27] 
RESULTS 
Table – 1 shows wheat alpha-amylase activity of 
neohesperidin. Neohesperidin inhibited alpha-amylase dose 
dependently. The percentage inhibition of neohespiridin was 
55.17% at highest concentration (100 μg/ml). IC50 value of 
acarbose, diabecon and neohesperidin was 34.13, 65.85 and 
82.64 μg/ml. Figure – 1 shows standard curve for acarbose. 
Table – 2 shows salivary alpha-amylase activity of 
neohesperidin. Neohesperidin inhibited alpha-amylase dose 
dependently. The percentage inhibition of neohespiridin was 
48.77% at highest concentration (100 μg/ml). IC50 value of 
acarbose, diabecon and neohesperidin was 32.97, 34.22 and 
40.65μg/ml. Figure – 2 shows standard curve for acarbose. 
Table – 3 shows fungal alpha-amylase activity of 
neohesperidin. Neohesperidin inhibited alpha-amylase dose 
dependently. The percentage inhibition of neohespiridin was 
25.25% at highest concentration (100 μg/ml). IC50 value of 
acarbose, diabecon and neohesperidin was 37.00, 80.20 and 
58.21μg/ml. Figure – 3 shows standard curve for acarbose. 
Table – 4 shows rat small intestine from alpha-glucosidaseof 
neohesperidin. Neohesperidin inhibited alpha-amylase dose 
dependently. The percentage inhibition of neohespiridin was 
22.98% at highest concentration (100 μg/ml). IC50 value of 
acarbose, diabecon and neohesperidin was 39.13, 59.62 and 
73.03μg/ml. Figure – 4 shows standard curve for acarbose. 
Table – 5 shows alpha-glucosidase inhibitory activity of 
neohesperidin obtained from B. stearothermophil. 
Neohesperidin inhibited alpha-amylase dose dependently. 
The percentage inhibition of neohespiridin was 8.51% at 
highest concentration (100 μg/ml). IC50 value of acarbose, 
diabecon and neohesperidin was 466.21, 418.29 and 
554.59μg/ml. Figure – 5 shows standard curve for acarbose. 
Table – 6 shows alpha-glucosidase inhibitory activity of 
neohesperidin obtained from baker’s yeast. Neohesperidin 
inhibited alpha-amylase dose dependently. The percentage 
inhibition of neohespiridin was 51.55% at highest 
concentration (100 μg/ml). IC50 value of acarbose, diabecon 
and neohesperidin was 63.23, 79.09 and 57.02μg/ml. Figure 
– 6 shows standard curve for acarbose.  Table – 7 shows 
inhibitory activity of neohesperidine on sucrase from rat 
intestine. Neohesperidin inhibited surase dose dependently. 
The percentage inhibition of neohespiridin was 61.11% at 
highest concentration (100 μg/ml). IC50 value of acarbose, 
diabecon and neohesperidin was 32.22, 49.78 and 87.69 
μg/ml. Figure – 7 shows standard curve for acarbose. 
 
Table no. – 1 Wheat alpha-amylase activity of neohesperidin 
S. No. Concentration 
(μg/ml) 
Percentage inhibition IC50(μg/ml) 
Acarbose Diabecon Neohesperidin Acarbose Diabecon Neohesperidin 
1.  20 47.58±3.47 34.02±2.19 30.11±3.19 34.13 65.85 82.64 
2.  40 48.36±0.83 41.84±2.65 38.85±0.82 
3.  60 60.45±2.79 45.51±0.39 42.3±1.61 
4.  80 67.12±4.25 52.87±2.93 49.42±2.82 
5.  100 77.93±2.1 65.28±4.47 55.17±4.15 
 
    
Fig. no. 1: Wheat alpha-amylase (Acarbose). 
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Table no. – 2 Salivary alpha-amylase activity of neohesperidin 
S. No. Concentration 
(μg/ml) 
Percentage inhibition IC50 (μg/ml) 
Acarbose Diabecon Neohesperidin Acarbose Diabecon Neohesperidin 
1.  20 52.45±8.29 40.34±10.67 37.71±6.14 32.97 34.22 40.65 
2.  40 55.61±4.5 49.99±4.02 49.12±3.16 
3.  60 70.87±4.7 52.63±5.26 65.28±2.32 
4.  80 69.26±2.74 62.27±7.79 70.17±2.31 
5.  100 73.86±0.88 60.52±3.98 48.77±6.63 
 
 
Fig. no. - 2: Salivary alpha-amylase (Acarbose) 
 
Table no. – 3 Fungal alpha-amylase activity of neohesperidin 
S. No. Concentration 
(μg/ml) 
Percentage inhibition IC50 (μg/ml) 
Acarbose Diabecon Neohesperidi
n 
Acarbose Diabecon Neohespe
ridin 
1.  20 47.59±4.93 44.97±6.2 25.11±4.55 25.25 37.00 80.20 
2.  40 56.72±1.68 51.36±4.55 36.3±1.72 
3.  60 59.81±3.22 57.07±2.96 41.78±1.72 
4.  80 68.94±6.2 60.95±3.81 49.08±2.38 
5.  100 74.65±4.45 69.63±3.07 58.21±3.37 
 
 
Fig. no. - 3: alpha-amylase (Acarbose) 
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Table no. – 4 Rat small intestines from alpha-glucosidase 
S. No. Concentration 
(μg/ml) 
Percentage inhibition IC50 (μg/ml) 
Acarbose Diabecon Neohesperidi
n 
Acarbo
se 
Diabeco
n 
Neohesperidin 
1.  20 53.07±2.99 43.94±3.67 28.65±4.41 22.98 39.13 59.62 
2.  40 60.08±4.59 49.04±3.67 38.21±1.32    
3.  60 63.47±6.62 55.83±5.42 46.28±1.88 
4.  80 74.09±3.7 69.42±7.15 65.2±1.12 
5.  100 80.67±2.95 77.49±1.7 73.03±1.88 
 
             
Fig. no. - 4: Rat small intestine from alpha-glucosidase (Acarbose) 
 
Table no. – 5 Alpha-glucosidase from B. stearothermophil 
S. No. Concentration 
(μg/ml) 
Percentage inhibition IC50 (μg/ml) 
Acarbose Diabecon Neohesperidin Acarbose Diabecon Neohesperidin 
1.  20 6.24±0.31 2.99±0.51 1.3±0.21 466.21 418.29 554.59 
2.  40 7±0.38 5.5±0.22 3.25±0.21    
3.  60 9.93±0.78 7.69±1.4 4.9±0.66 
4.  80 12.33±0.63 10.03±0.85 7.09±0.95 
5.  100 13.5±1.26 12.59±0.96 8.51±1.14 
 
 
Fig. no. - 5: Alpha-glucosidase from B.stearothermophil (Acarbose) 
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Table no. – 6 Alpha-glucosidase from baker’s yeast 
S. No. Concentration 
(μg/ml) 
Percentage inhibition IC50 (μg/ml) 
Acarbose Diabecon Neohesperidin Acarbose Diabecon Neohesperidin 
1 20 27.12±4.39 10.78±2.46 6.86±3.53 57.02 63.23 79.09 
2 40 39.54±7.21 19.6±0.56 14.7±4.42    
3 60 52.61±7.07 33.33±1.13 26.14±6.23 
4 80 63.72±5.96 47.05±3.14 36.27±5.4 
5 100 76.14±2.9 66.42±4.3 51.55±5.84 
 
 
Fig. no. -  6: Alpha-glucosidase from baker’s yeast (Acarbose) 
 
Table no. – 7 Sucrase from rat small intestine 
S. No. Concentration 
(μg/ml) 
Percentage inhibition IC50 (μg/ml) 
Acarbose Diabecon Neohesperidin Acarbose Diabecon Neohesperidin 
1.  20 42.3±8.72 26.01±6.68 11.96±1.54 32.22 49.78 87.69 
2.  40 54.42±5.74 45.73±7.99 25.63±4.62    
3.  60 66.65±4.43 61.1±6.67 29.05±3.33 
4.  80 78.2±2.67 72.64±7.1 42.64±3.68 
5.  100 86.74±1.13 78.2±4.5 61.11±1.54 
 
             
Fig. no. - 7: Sucrase from rat small intestine (Acarbose) 
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DISCUSSION: 
According to the results obtained at different concentrations, 
we observed that the anti-diabetic inhibitory activities of the 
enzyme which hydrolyze carbohydrates depends on the 
concentration of Neohesperidin pure compound. Result 
observed by neohesperidin on different enzymes are the 
alpha-amylase (wheat alpha-amylase, salivary amylase and 
fungal amylase.), alpha-glucosidase (rat small intestine 
glucosidase, baker’s yeast, B.stearothermophil) and Sucrase 
rat intestinal enzyme that is showed better inhibitory 
activity as compare to alpha-glucosidase and Sucrase.  
Inhibition of enzymes involved in the hydrolysis of 
carbohydrates such as alpha amylase & alpha glucosidase 
has been exploited as a therapeutic approach for controlling 
postprandial hyperglycemia. Alpha glucosidase (intestinal 
alpha glucosidase) catalyzes the breakdown of disaccharides 
to liberate glucose which is later absorbed into the blood 
circulation. Inhibition of these enzymes would slow down 
the breakdown of starch in the gastro-intestinal tract, thus 
reducing postprandial hyperglycemia. 
In recent diabetic treatments, α-amylase and α-glucosidase 
inhibitors are most potented because they increase post-
prandial hyperglycemic conditions. The antioxidant ability of 
phenolic compounds in fruits and vegetables could be 
attributed to their properties such as reducing agents, 
hydrogen donors, singlet hydrogen quenchers and/or metal 
ion- cheaters. Therefore, natural antioxidants can also inhibit 
the key enzymes α-amylase, α-glucosidase and control the 
post-prandial hyperglycemic conditions which are a 
potential approach to cure the type 2 diabetes mellitus. 
Flavonoids are a prominent group of secondary metabolites 
in citrus fruits that may possess biological activity and have 
beneficial effects on human health as antimicrobial, anti-
inflammatory, anti-diabetic, anti-cholesterolemic, 
antioxidant and anti-cancer agents. Flavonoids are reported 
to possess strong free radical scavenging activities based on 
their ability to act as hydrogen or electron donors and 
chelate transition metals. 
Among the ubiquitous flavonoids found in the plant kingdom, 
NHP is one of the several flavanones glycosides unique to 
Citrus and specific citrus cultivars. Studies have shown that 
supplemental natural phenolic from different fruit sources 
represent a potential strategy as adjunct therapy. Recently, 
extensive studies of citrus flavanones have been reported to 
have potential hypoglycaemic effect. 
Neohesperidin were found to be the most abundant 
flavonoids in grapefruit and Seville orange (C. aurantium), 
and their concentration can be used to differentiate orange 
juices from grapefruit and sour orange sources. Huyou fruit 
is most likely a hybrid between sour orange and pummelo, 
both of which have a bitter taste. 
In the present study simultaneous purified neohesperidin 
purchased from sigma-aldrich neohesperidin are reported in 
previous review literature studies showed anti-oxidant, anti-
diabetic and anti-lipidemic activities. In-vitro carbohydrate 
metabolizing enzyme based inhibitory method used. In 
above experimental study results have been showed that 
enzyme inhibitory activity such as neohesperidin were 
shown to have a significantly higher inhibitory activity on 
alpha-amylase with compare to alpha-glucosidase & Sucrase. 
Recently the Neohesperidin showed a significant inhibiting 
both alpha-amylase and alpha-glucosidase. The alpha-
amylase different sources are wheat alpha-amylase IC50-
82.64, salivary alpha-amylase IC50-40.65and fungal alpha-
amylase IC50-80.20. This result concluded that 
Salivary alpha-amylase > fungal alpha-amylase > wheat 
alpha-amylase. 
Alpha-glucosidase obtained from different source is rat small 
intestine alpha-glucosidase IC50-59.62, B. stearothermophil 
IC50-554.59, baker’s yeast IC50-79.09. Result calculated that  
Rat small intestine alpha-glucosidase > B.stearothermophil > 
baker’s yeast. 
Sucrase is significant result shown IC50-87.69 according to 
the results higher inhibitory activity shown Neohesperidin in 
alpha-amylase and less weak inhibitory activity on alpha-
glucosidase and Sucrase. The results obtained at different 
concentrations, we observed that the anti-diabetic inhibitory 
activities of the enzymes which hydrolyze carbohydrate 
depend on the concentration of flavonoids present in the 
Neohesperidin pure compound.   
Diabetes is characterized by high concentrations of blood 
sugar which can cause serious complications in the kidneys, 
eyes and cardiovascular system. The treatment of diabetes 
there-fore mainly focuses on reducing fluctuations in blood 
sugar and subsequent complications. The α-amylase and α-
glucosidase inhibitors are currently used for diabetic 
treatment as oral hypoglycemic agents. Acarbose is a 
commercially available enzyme inhibitor for type II diabetes. 
However, it is reported to cause various side effects such as 
abdominal distention, flatulence and possibly diarrhea. 
Searching for safe and effective inhibitors from natural 
sources are of emerging interest. The inhibitory effects of the 
neohesperidin, acarbose as a standard established anti-
diabetic drug and marketed herbal formulation are Diabecon 
(Himalaya tablet formulation) are used to inhibitory activity 
comparison neohesperidin on α-amylase, α-glucosidase and 
Sucrase. Than result obtained neohesperidin acarbose and 
Diabecon herbal anti-diabetic drug are nearby activity 
showed. 
CONCLUSION: 
In present study pure Neohesperidin Phytoconstituent 
purchased from Sigma-Aldrich, Japan. Early reported that it’s 
having a potent anti-oxidant, anti-diabetic and anti-lipidemic. 
In above In-vitro experiment carbohydrate metabolizing 
enzyme based inhibitory methods used. It was concluded 
that if so better activity in alpha-amylase as compare to 
alpha-glucosidase and Sucrase. 
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